Biology and treatment of multiple myeloma

Patrizia Tosi, Barbara Gamberi, Nicola Giuliani

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a B cell malignancy that accounts for 10% of all hematologic cancers. In recent years much has been learned regarding the biology of the myeloma clone; specifically on the chromosomal alterations that can be more frequently found and on the involved oncogenes. It has been also demonstrated that, in MM, bone marrow microenvironment, both in its cellular (stromal cells, osteoblasts, osteoclasts, endothelia) and protein (extracellular matrix) components, plays an important role in promoting growth and survival of malignant plasma cells. Much of this knowledge will be translated into a better patients treatment; although high-dose therapy programs can be considered the treatment of choice for patients aged 70 or younger, novel drugs, targeting MM clone in its microenvironment can be incorporated into these therapeutic programs improving response rate and patients survival.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume12
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Multiple Myeloma
Clone Cells
Extracellular Matrix Proteins
Osteoclasts
Therapeutics
Drug Delivery Systems
Stromal Cells
Plasma Cells
Osteoblasts
Oncogenes
Endothelium
Neoplasms
B-Lymphocytes
Survival Rate
Bone Marrow
Growth

Keywords

  • Microenvironment
  • Myeloma
  • Oncogenes
  • Stem cell transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Biology and treatment of multiple myeloma. / Tosi, Patrizia; Gamberi, Barbara; Giuliani, Nicola.

In: Biology of Blood and Marrow Transplantation, Vol. 12, No. SUPPL. 1, 01.2006, p. 81-86.

Research output: Contribution to journalArticle

Tosi, Patrizia ; Gamberi, Barbara ; Giuliani, Nicola. / Biology and treatment of multiple myeloma. In: Biology of Blood and Marrow Transplantation. 2006 ; Vol. 12, No. SUPPL. 1. pp. 81-86.
@article{1e85d7456a1a4e13a414d95eff50025b,
title = "Biology and treatment of multiple myeloma",
abstract = "Multiple myeloma (MM) is a B cell malignancy that accounts for 10{\%} of all hematologic cancers. In recent years much has been learned regarding the biology of the myeloma clone; specifically on the chromosomal alterations that can be more frequently found and on the involved oncogenes. It has been also demonstrated that, in MM, bone marrow microenvironment, both in its cellular (stromal cells, osteoblasts, osteoclasts, endothelia) and protein (extracellular matrix) components, plays an important role in promoting growth and survival of malignant plasma cells. Much of this knowledge will be translated into a better patients treatment; although high-dose therapy programs can be considered the treatment of choice for patients aged 70 or younger, novel drugs, targeting MM clone in its microenvironment can be incorporated into these therapeutic programs improving response rate and patients survival.",
keywords = "Microenvironment, Myeloma, Oncogenes, Stem cell transplantation",
author = "Patrizia Tosi and Barbara Gamberi and Nicola Giuliani",
year = "2006",
month = "1",
doi = "10.1016/j.bbmt.2005.09.008",
language = "English",
volume = "12",
pages = "81--86",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Biology and treatment of multiple myeloma

AU - Tosi, Patrizia

AU - Gamberi, Barbara

AU - Giuliani, Nicola

PY - 2006/1

Y1 - 2006/1

N2 - Multiple myeloma (MM) is a B cell malignancy that accounts for 10% of all hematologic cancers. In recent years much has been learned regarding the biology of the myeloma clone; specifically on the chromosomal alterations that can be more frequently found and on the involved oncogenes. It has been also demonstrated that, in MM, bone marrow microenvironment, both in its cellular (stromal cells, osteoblasts, osteoclasts, endothelia) and protein (extracellular matrix) components, plays an important role in promoting growth and survival of malignant plasma cells. Much of this knowledge will be translated into a better patients treatment; although high-dose therapy programs can be considered the treatment of choice for patients aged 70 or younger, novel drugs, targeting MM clone in its microenvironment can be incorporated into these therapeutic programs improving response rate and patients survival.

AB - Multiple myeloma (MM) is a B cell malignancy that accounts for 10% of all hematologic cancers. In recent years much has been learned regarding the biology of the myeloma clone; specifically on the chromosomal alterations that can be more frequently found and on the involved oncogenes. It has been also demonstrated that, in MM, bone marrow microenvironment, both in its cellular (stromal cells, osteoblasts, osteoclasts, endothelia) and protein (extracellular matrix) components, plays an important role in promoting growth and survival of malignant plasma cells. Much of this knowledge will be translated into a better patients treatment; although high-dose therapy programs can be considered the treatment of choice for patients aged 70 or younger, novel drugs, targeting MM clone in its microenvironment can be incorporated into these therapeutic programs improving response rate and patients survival.

KW - Microenvironment

KW - Myeloma

KW - Oncogenes

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=29844453760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29844453760&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.09.008

DO - 10.1016/j.bbmt.2005.09.008

M3 - Article

C2 - 16399590

AN - SCOPUS:29844453760

VL - 12

SP - 81

EP - 86

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - SUPPL. 1

ER -